Biopharma BD Report | Q3 2025
A data-driven look at Q3 2025 biopharma dealmaking, highlighting rising M&A activity, oncology’s continued momentum and shifting investment trends across IPOs, private placements and global partnerships.
The biopharma dealmaking landscape continued to evolve in Q3 2025, marked by an upswing in M&A activity, shifting investor priorities and steady momentum across high-value therapeutic areas. Our latest Biopharma BD Report breaks down the signals shaping how companies partner, invest and advance their pipelines in an increasingly competitive market.
Inside this report:
- Key Q3 partnership and M&A trends, including top-value deals
- Therapeutic areas attracting the strongest investment and activity
- How macro financing patterns are influencing BD strategies
- What these shifts signal for 2026 planning across R&D, commercial and corporate development
Fill out the form below to get the intelligence your teams need to navigate market uncertainty.
Related Content
Looking for exclusive insight?
